Landmark Genetic Analysis Places the Earliest Warning Signs of Alzheimer’s on the Disease Map

For decades, one of the most frustrating puzzles in Alzheimer’s research has been what to make of people who complain that their memory is slipping, yet who sail through every standard neuropsychological test. Are these complaints the faintest whisper of the disease, or simply the noise of normal aging and anxiety? A new systematic review and meta-analysis published in the Journal of Neurology offers the most comprehensive answer yet, and it does so through the lens of the single most powerful genetic risk factor for sporadic Alzheimer’s disease: the apolipoprotein E ε4 allele, known to almost everyone in the field simply as APOE ε4. By pooling data from 49 studies spanning more than two decades and four continents, an Italian research team has shown that the genetic signature of people with subjective cognitive decline sits precisely where theorists have long suspected it should—between healthy individuals and those with mild cognitive impairment.

The numbers tell a strikingly clean story. Among people with subjective cognitive decline, 28.3 percent carried at least one APOE ε4 allele. Among those with mild cognitive impairment, the figure climbed to 41.0 percent, while cognitively normal individuals carried the allele at a rate of just 22.0 percent. In statistical terms, the odds of being an ε4 carrier were significantly higher in the subjective decline group than in healthy controls, with an odds ratio of 1.28, and significantly higher still in the mild impairment group compared with the subjective decline group, at 1.48. That stepped gradient—rising steadily from normal cognition through subjective complaints to objective impairment—is exactly the pattern one would expect if subjective cognitive decline truly represents a transitional stage on the Alzheimer’s continuum rather than a clinically meaningless complaint.

To appreciate why this matters, it helps to understand how the field’s thinking has evolved. Alzheimer’s disease, which accounts for roughly 60 percent of all dementia cases worldwide, is no longer viewed as a binary diagnosis that arrives only when memory loss becomes undeniable. Instead, clinicians and researchers now describe a biological and clinical continuum: an asymptomatic stage in which amyloid and tau biomarkers are positive but cognition is intact, followed by a transitional phase in which very mild changes are perceived by the patient but remain within normal limits on formal testing, and finally mild cognitive impairment and overt dementia. The 2024 revised criteria from the Alzheimer’s Association Workgroup formalized this staging, and the transitional phase maps directly onto the syndrome of subjective cognitive decline. Interventions, most studies suggest, work best when applied early—which makes identifying who in this earliest phase is genuinely at risk a matter of urgent practical importance.

The trouble has always been definition. Before 2014, researchers used a bewildering array of overlapping labels—subjective memory impairment, subjective cognitive complaints, subjective memory concerns—often interchangeably and inconsistently. That year, Frank Jessen and colleagues provided a unified framework, defining subjective cognitive decline as a persistent, self- or informant-reported worsening of cognition, most often memory, in people whose performance on standardized tests remains normal and who show no abnormalities on neurological examination. The same group proposed a set of enrichment features, the so-called SCD-plus criteria, designed to flag cases more likely to reflect preclinical Alzheimer’s: onset at age 60 or older, symptoms beginning within the past five years, a sense of decline relative to peers, and genuine worry about the changes. Even with these tools, however, biomarker findings in this population have remained stubbornly heterogeneous, and previous reviews had produced conflicting results about whether APOE ε4 was enriched at all.

That is precisely the discrepancy the new analysis resolves. An earlier systematic review had concluded that APOE ε4 prevalence in subjective decline was essentially the same as in cognitively normal people—a finding that seemed to undercut the whole staging framework. The authors of the new meta-analysis, led by Paolo Alonge and Roberto Monastero of the University of Palermo, argue that the conflict stems largely from how studies defined the syndrome. The earlier review included studies using the older, looser classifications, whereas the new analysis applied stringent inclusion criteria aligned with the Subjective Cognitive Decline Initiative: a cognitive complaint in one or more domains, exclusion of objective impairment through formal neuropsychological testing, and exclusion of psychiatric, neurological, or systemic conditions that could muddy the picture. Under those stricter standards, the genetic gradient emerges clearly.

The methodological machinery behind the result is considerable. The team searched MEDLINE, Web of Science, and Scopus from inception to April 15, 2026, screening 474 records after duplicate removal and ultimately including 49 studies—26 cross-sectional and 23 prospective—conducted across Europe, North America, Asia, Australia, and the Middle East, with publication years ranging from 2005 to 2026. They used random-effects models with restricted maximum likelihood estimation, logit-transformed the response variable to satisfy normality assumptions, assessed heterogeneity with Cochran’s Q and the I-squared statistic, and probed publication bias with Egger’s test supplemented by Duval and Tweedie’s trim-and-fill adjustment. A leave-one-out influence analysis, using diagnostics such as Cook’s distance and DFFITS, confirmed that no single study was driving the pooled estimates. Notably, the funnel plot asymmetry pointed in the direction opposite to classical publication bias, with smaller studies tending to report lower ε4 prevalence—a known artifact of Egger’s test when applied to proportions—so the authors concluded that true publication bias was unlikely to distort the findings.

One of the most technically interesting aspects of the analysis is how the team handled correlated effect sizes. Because the odds ratios comparing mild impairment versus subjective decline and normal cognition versus subjective decline share a common reference group, they are not statistically independent. Pooling them naively would understate uncertainty. Instead, the researchers used a multivariate meta-analytic framework via the Mixmeta package, incorporating the variance–covariance matrix of the odds ratios so that within-study correlations were properly accounted for. Twenty-six studies contributed to this model. Meta-regressions added another layer, testing whether the proportion of female participants, mean age, and years of education explained the substantial between-study heterogeneity, which reached an I-squared of 90.2 percent in the subjective decline cohort.

Those meta-regressions produced findings with real biological intrigue. In the subjective decline groups, mean age showed a significant negative association with ε4 carrier prevalence, accounting for about 15 percent of the between-study variance, while education showed a significant positive association. The authors offer two plausible interpretations for the age effect: a survival bias, or the possibility that ε4 carriers convert more rapidly to more advanced stages of disease, depleting them from older subjective-decline cohorts. The education effect may reflect cognitive reserve—the idea that highly educated individuals notice and report subtle cognitive changes earlier, even while their test performance remains formally normal—or simply selection bias in who ends up in memory clinic studies. Sex distribution, by contrast, showed no significant effect. In the cognitively normal groups, both age and education correlated positively with ε4 prevalence, with education alone explaining a remarkable 91.9 percent of the between-study variance.

The cross-sectional picture is complemented by a more consistent longitudinal one. The three prospective studies that directly examined APOE ε4 in subjective decline all reported an increased risk of conversion to objective cognitive impairment among carriers, and observational cohorts linked ε4 status to faster cognitive decline and greater changes in cerebrospinal fluid and plasma biomarkers—though not uniformly, with a few studies reporting no biomarker association. This matters therapeutically as well: APOE ε4 is now a reliable predictor of amyloid-related imaging abnormalities during treatment with the new anti-amyloid monoclonal antibodies, and the allele itself is being pursued as a drug target through gene editing, gene silencing, and expression regulation. Studies of APOE genotype disclosure suggest that learning one’s genetic risk influences future planning and health behaviors, with psychological effects that appear generally manageable—raising clinical and ethical questions as genetic testing edges into early cognitive assessment.

The authors are careful about limitations. Heterogeneity remained high even after meta-regression, reflecting the fact that subjective cognitive decline, like mild cognitive impairment, is an umbrella syndrome encompassing vascular, degenerative, and other etiologies rather than a single disease. Many studies were conducted in memory clinics, potentially enriching samples with higher-risk individuals, and genotype data were often reported merely as descriptive characteristics rather than primary outcomes. Regional differences in ε4 frequency—lower in Mediterranean and Asian populations than in Northern European and North American cohorts—could not be formally subgrouped. Still, the central conclusion stands: the prevalence of APOE ε4 in subjective cognitive decline falls squarely between normal cognition and mild impairment, vindicating the staging model. The path forward, the authors argue, lies in multimodal risk models that integrate genetics with fluid and imaging biomarkers, clinical variables, and other genes—a strategy that could eventually deliver personalized counseling and earlier, better-targeted intervention for the people who need it most.

Subject of Research: APOE ε4 allele prevalence in subjective cognitive decline as an intermediate stage of the Alzheimer's disease continuum

Article Title: APOE in subjective cognitive decline: a systematic review and meta-analysis

Article References: Alonge, P., Baiamonte, L., Gerardi, G., Torrente, A., Lo Mauro, E., Veronese, N., Labate, A., & Monastero, R. (2026). APOE in subjective cognitive decline: a systematic review and meta-analysis. Journal of Neurology, 273(9), Article 556. https://doi.org/10.1007/s00415-026-14077-5

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14077-5

Keywords: Alzheimer's disease, APOE ε4, subjective cognitive decline, mild cognitive impairment, meta-analysis, genetic risk factor, dementia, biomarkers, neuropsychology, risk stratification, Journal of Neurology, preclinical Alzheimer's